Commonwealth Equity Services Inc reduced its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 339,701 shares of the pharmaceutical company’s stock after selling 13,539 shares during the period. Commonwealth Equity Services Inc’s holdings in GlaxoSmithKline PLC were worth $13,791,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Proficio Capital Partners LLC lifted its position in shares of GlaxoSmithKline PLC by 16.1% during the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after buying an additional 457 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in shares of GlaxoSmithKline PLC by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 64 shares in the last quarter. FTB Advisors Inc. lifted its position in shares of GlaxoSmithKline PLC by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after buying an additional 539 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of GlaxoSmithKline PLC by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after buying an additional 148 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of GlaxoSmithKline PLC by 93.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after buying an additional 1,955 shares in the last quarter. 9.32% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/17/commonwealth-equity-services-inc-has-13-79-million-stake-in-glaxosmithkline-plc-gsk.html.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.00% of the stock is owned by corporate insiders.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded down $0.08 on Friday, hitting $35.11. The stock had a trading volume of 1,263,481 shares, compared to its average volume of 3,443,574. The stock has a market cap of $85,050.00, a PE ratio of 12.37, a price-to-earnings-growth ratio of 1.93 and a beta of 1.00. GlaxoSmithKline PLC has a twelve month low of $34.72 and a twelve month high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This represents a $2.01 annualized dividend and a dividend yield of 5.74%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. GlaxoSmithKline PLC’s dividend payout ratio is 159.20%.

A number of research analysts recently commented on GSK shares. TheStreet raised GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Argus reissued a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Wednesday, October 18th. Investec cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $44.33.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.